Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999853 · ClinicalTrials.gov registry record · Phase 1
Butyrate Adjuvant Therapy for Type 1 Diabetes
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03999853: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03999853 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03999853, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Interventions
- DRUG BKR-017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999853
The ClinicalTrials.gov registry entry for NCT03999853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKR-017 is the first listed.
NCT03999853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03999853 about?
NCT03999853 is a clinical study titled "Butyrate Adjuvant Therapy for Type 1 Diabetes". The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
What is the current status of trial NCT03999853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-07-28. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT03999853?
The interventions under investigation include: BKR-017 (DRUG).
Who is sponsoring clinical trial NCT03999853?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.